NCCN Adjuvant Therapy for Breast Cancer Task Force Members *Robert W. Carlson, MD / Chair#† ¶¶ Stanford Hospital and Clinics Donald A. Berry, PhD†† The University of Texas M. D. Anderson Cancer Center *Elizabeth Brown, MD National Comprehensive
Search Results
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer
Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force
Does Use of the Adjuvant! Model Influence Use of Adjuvant Therapy Through Better Risk Communication?
Jeffrey K. Belkora, David W. Hutton, Dan H. Moore, and Laura A. Siminoff
P atients with breast cancer who are at relatively low risk for recurrence or mortality after local therapy (surgery with or without radiation) face a “grey zone” decision about whether to undergo adjuvant therapy. 1 The choice of therapy
Counterpoint: Adjuvant Therapy in Stage II Colon Cancer: Pain Not Justified by the Gain
Katherine Van Loon and Alan P. Venook
Adjuvant therapy for colon cancer evolved in an additive fashion. In the 1980s, 5-fluorouracil (5-FU) administered as a daily bolus regimen made the first positive impact of any therapy on colon cancer survival. 1 The ensuing decade of research
Omission of Adjuvant Therapy After Gastric Cancer Resection: Development of a Validated Risk Model
Jashodeep Datta, Matthew T. McMillan, Eric K. Shang, Ronac Mamtani, Russell S. Lewis Jr, Rachel R. Kelz, Ursina Teitelbaum, John P. Plastaras, Jeffrey A. Drebin, Douglas L. Fraker, Giorgos C. Karakousis, and Robert E. Roses
incorporated into practice guidelines for GA management in the United States. Subsequently, several retrospective population-based studies have reaffirmed the benefit of adjuvant therapy in patients undergoing curative-intent gastrectomy. 7 – 9 Based on these
Prognostic Value of Nodal Response After Preoperative Treatment of Gastric Adenocarcinoma
Yvonne H. Sada, Brandon G. Smaglo, Joy C. Tan, Hop S. Tran Cao, Benjamin L. Musher, and Nader N. Massarweh
Although perioperative chemotherapy and postoperative chemoradiation are the 2 evidence-based options for gastric cancer, 4 , 6 ongoing multicenter trials are investigating whether strategies that move most or all of the adjuvant therapy to the
Point: Interferon-α for Adjuvant Therapy for Melanoma Patients
Michael S. Sabel and Vernon K. Sondak
: 3635 – 3648 . 2 Dickler MN Coit DG Myers ML . Adjuvant therapy of malignant melanoma . Surg Oncol Clin N Am 1997 ; 6 : 793 – 812 . 3 Pfeffer LM Dinarello CA Herberman RB . Biological properties of recombinant alpha
Patient Navigation for Timely, Guideline-Adherent Adjuvant Therapy for Head and Neck Cancer: A National Landscape Analysis
Evan M. Graboyes, Michelle Chappell, Kelsey A. Duckett, Katherine Sterba, Chanita Hughes Halbert, Elizabeth G. Hill, Bhishamjit Chera, Jessica McCay, Sidharth V. Puram, Salma Ramadan, Vlad C. Sandulache, Russel Kahmke, Brian Nussenbaum, Anthony J. Alberg, Electra D. Paskett, and Elizabeth Calhoun
-adherent adjuvant therapy and worse oncologic outcomes for patients with HNC. 2 – 7 In addition, the metric was selected because there is a quality-of-care gap, with approximately 50% of patients failing to commence PORT within the recommended 6-week interval. 2
CLO19-040: The Role of Adjuvant Therapy in Patients With Pathological T2N0 Resected Gastric Adenocarcinoma
John Khoury, David Macari, Daniel Ezekwudo, Ayoda Werede, and Ishmael A. Jaiyesimi
Background: There is controversy surrounding the benefit of adjuvant therapy for patients with pT2N0, stage IB gastric adenocarcinoma following surgical resection. Methods: Patients with T2N0 gastric adenocarcinoma (tumor invasion into the
Where Are We With Adjuvant Therapy of Stage III and IV Melanoma in 2009?
Leslie A. Fecher and Keith T. Flaherty
alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 . J Clin Oncol 1996 ; 14 : 7 – 17 . 11 Kirkwood J Manola J Ibrahim J . A pooled analysis of eastern cooperative
Serial Assessment of Urinary Incontinence in Breast Cancer Survivors Undergoing (Neo)Adjuvant Therapy
Christopher P. Chung, Carolyn Behrendt, Louise Wong, Sarah Flores, and Joanne E. Mortimer
Questionnaire (IIQ-7) 15 before and 3 months after initiation of (neo)adjuvant therapy. Patients with metastatic cancer or currently or previously undergoing treatment by a urologist were excluded from participation. Participants were approached by the treating
